» Articles » PMID: 23227359

African Ancestry is a Predictor Factor to Secondary Progression in Clinical Course of Multiple Sclerosis

Overview
Journal ISRN Neurol
Specialty Neurology
Date 2012 Dec 11
PMID 23227359
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background. Studies on the clinical course of multiple sclerosis have indicated that certain initial clinical factors are predictive of disease progression. Regions with a low prevalence for disease, which have environmental and genetic factors that differ from areas of high prevalence, lack studies on the progressive course and disabling characteristics of the disease. Objective. To analyse the long-term evolution to the progressive phase of the relapsing-remitting multiple sclerosis and its prognosis factors in mixed population. Methods. We performed a survival study and logistic regression to examine the influence of demographic and initial clinical factors on disease progression. Among 553 relapsing-remitting patients assisted at a Brazilian reference centre for multiple sclerosis, we reviewed the medical records of 150 patients who had a disease for ten or more years. Results. African ancestry was a factor that conferred more risk for secondary progression followed by age at the onset of the disease and the number of relapses in the year after diagnosis. A greater understanding of the influence of ancestry on prognosis serves to stimulate genetics and pharmacogenomics research and may clarify the poorly understood neurodegenerative progression of MS.

Citing Articles

Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients.

Telesford K, Amezcua L, Tardo L, Horton L, Lund B, Reder A Front Immunol. 2023; 14:1172993.

PMID: 37215103 PMC: 10196635. DOI: 10.3389/fimmu.2023.1172993.


Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).

Okai A, Amezcua L, Berkovich R, Chinea A, Edwards K, Steingo B Neurol Ther. 2019; 8(2):367-381.

PMID: 31654272 PMC: 6858901. DOI: 10.1007/s40120-019-00159-2.


Application of the McDonald criteria in Latin America.

Patrucco L Mult Scler J Exp Transl Clin. 2017; 3(3):2055217317721943.

PMID: 28979793 PMC: 5617101. DOI: 10.1177/2055217317721943.


Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.

Wing A, Hygino J, Ferreira T, Kasahara T, Barros P, Sacramento P Immunology. 2016; 147(2):212-20.

PMID: 26781085 PMC: 4717237. DOI: 10.1111/imm.12552.


Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study.

Papais-Alvarenga R, Vasconcelos C, Carra A, Soto de Castillo I, Florentin S, de Bedoya F PLoS One. 2015; 10(7):e0127757.

PMID: 26222205 PMC: 4519274. DOI: 10.1371/journal.pone.0127757.

References
1.
Howard G, Howard V . Ethnic disparities in stroke: the scope of the problem. Ethn Dis. 2002; 11(4):761-8. View

2.
Johnson B, Wang J, Taylor E, Caillier S, Herbert J, Khan O . Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 2009; 11(4):343-50. PMC: 2880217. DOI: 10.1038/gene.2009.81. View

3.
Stankoff B, Mrejen S, Tourbah A, Fontaine B, Lyon-Caen O, Lubetzki C . Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology. 2007; 68(10):779-81. DOI: 10.1212/01.wnl.0000256732.36565.4a. View

4.
Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y . Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009; 73(20):1616-23. PMC: 2881858. DOI: 10.1212/WNL.0b013e3181c1e44f. View

5.
Koch M, Kingwell E, Rieckmann P, Tremlett H . The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010; 81(9):1039-43. DOI: 10.1136/jnnp.2010.208173. View